Global Preclinical Imaging Market, By Product (Systems and Services), Reagents (Preclinical Optical Imaging Reagents, Preclinical Nuclear Imaging Reagents, Preclinical MRI Contrast Agents, Preclinical Ultrasound Contrast Agents, and Preclinical CT Contrast Agents), Application (Research and Development, Drug Discovery, Bio-Distribution, Cancer Cell Detection, Bio-Markers, and Others), End User (Contract Research Organization, Pharmaceutical & Biotech Companies, Academic & Government Research Institutes, Diagnostics Center, and Others) – Industry Trends and Forecast to 2030.
Preclinical Imaging Market Analysis and Size
The global preclinical imaging market is the industry involved in providing imaging solutions and technologies for conducting research and experimentation on animals (usually rodents) in the preclinical stage of drug development and medical research. These imaging techniques are crucial for assessing the safety and efficacy of potential drug candidates and medical treatments before they advance to clinical trials involving human subjects. Preclinical imaging allows researchers and pharmaceutical companies to evaluate the effects of drug candidates on living organisms before moving to human trials. This helps in identifying potential issues, optimizing dosage regimens, and reducing the risk of adverse effects in later stages.
Data Bridge Market Research analyzes that the global preclinical imaging market is expected to reach the value of USD 3,299,734.83 thousand by 2030, at a CAGR of 6.3% during the forecast period.
This market report also covers pricing analysis and technological advancements in depth.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Thousand, Volumes in Units, and Pricing in USD
|
|
Segments Covered
|
Product (Systems and Services), Reagents (Preclinical Optical Imaging Reagents, Preclinical Nuclear Imaging Reagents, Preclinical MRI Contrast Agents, Preclinical Ultrasound Contrast Agents, and Preclinical CT Contrast Agents), Application (Research and Development, Drug Discovery, Bio-Distribution, Cancer Cell Detection, BioMarkers, and Others), End User (Contract Research Organization, Pharmaceutical & Biotech Companies, Academic & Government Research Institutes, Diagnostics Center, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, U.K., Germany, Spain, France, Italy, Switzerland, Netherlands, Belgium, Turkey, Russia, Rest of Europe, China, Japan, Australia, South Korea, India, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, U.A.E., Israel, Saudi Arabia, Egypt, and Rest of Middle East and Africa
|
|
Market Players Covered
|
PerkinElmer Inc., FUJIFILM Visualsonics, Inc, Bruker, Hologic, Inc, Zeiss International, Agilent Technologies, Inc., Hamamatsu Photonics K.K., SOFIE, Cubresa Inc., Vieworks Co., Ltd., LI-COR, Inc., Aspect Imaging Ltd., Berthold Technologies GmbH & Co.KG, MILabs B.V, TriFoil Imaging, Mediso Ltd., IVIM Technology Inc., MR Solutions, Advanced Molecular Vision, Inc, AI4R, Photon etc, and KUB TECHNOLOGIES INC.
|
Market Definition
Preclinical imaging is the use of various imaging techniques and technologies to visualize and study biological processes, diseases, and drug responses in animal models before they are tested in humans. It involves the non-invasive imaging of animals, typically rodents, such as mice and rats, to gain insights into the underlying mechanisms of diseases and to evaluate the efficacy and safety of potential therapies.
Global Preclinical Imaging Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Increasing Technology Advancement in the Field of Imaging
Preclinical imaging refers to the use of various imaging modalities to visualize and study the biological processes in animals before clinical trials. These systems help researchers to gain insight into disease mechanisms, evaluate potential drug candidates, and monitor treatment efficacy. Technology advancement in the field of imaging is playing a crucial role in driving the growth of the global preclinical imaging market.
Modern imaging technologies, such as high-resolution magnetic resonance imaging (MRI), micro-computed tomography (micro-CT), and advanced ultrasound provide researchers with clearer and more detailed images of biological structures.
Furthermore, there have been significant improvements in image analysis and data processing algorithms. Advanced software tools and machine learning algorithms enable researchers to extract quantitative data from images, automate image processing tasks, and improve the accuracy and efficiency of data analysis. These advancements save time and enhance the reproducibility and reliability of preclinical studies.
High-resolution imaging techniques, multimodal imaging systems, and advanced image analysis algorithms are enhancing the capabilities of preclinical imaging and enabling researchers to gain deeper insights into disease mechanisms. Thus, the advancement in imaging technology is driving the growth of the global preclinical imaging market.
- Increasing Number of Investments and Funding in Research and Development
The increasing number of investments and funding in research and development (R&D) is a significant driver of the growth of the global preclinical imaging market. Organizations are allocating substantial resources to advance imaging technologies and support innovative research initiatives as the importance of preclinical imaging in drug discovery and development becomes more evident.
Investments and funding in R&D enable the development of novel preclinical imaging modalities and techniques. This financial support facilitates the improvement of imaging systems, software, and hardware, leading to enhanced image quality, resolution, and sensitivity. These advancements enable researchers to obtain more accurate and detailed information about biological processes, disease mechanisms, and treatment responses, driving the growth of the preclinical imaging market.
In addition, funding and investments contribute to the expansion of preclinical imaging facilities and infrastructure. Research institutions and pharmaceutical companies can establish dedicated preclinical imaging centers or upgrade existing facilities, ensuring access to state-of-the-art imaging equipment and expertise. This infrastructure development fosters collaboration, accelerates research, and attracts top talent, which may further drive the growth of the preclinical imaging market.
Moreover, investments and funding support preclinical research studies that utilize imaging technologies. Pharmaceutical companies, academic institutions, and government agencies provide financial support for preclinical trials, enabling researchers to investigate the safety, efficacy, and mechanism of action of potential therapeutic candidates. These studies generate valuable data that can inform clinical trial designs and aid in the development of new treatments, driving the demand for preclinical imaging technologies.
Furthermore, funding and investments in R&D also promote the translation of preclinical imaging research into clinical applications. Successful preclinical studies can attract further investment and partnerships, leading to the development of imaging techniques and technologies for human use. This expansion into clinical imaging applications further strengthens the preclinical imaging market.
Thus, the increasing number of investments and funding in research and development is a significant driver of the growth of the global preclinical imaging market.
Opportunity
- Increasing Adoption of Imaging Systems for Preclinical Purposes
The pharmaceutical and biotechnology industries are continually searching for novel drug candidates to address unmet medical needs. Preclinical imaging allows for a more comprehensive understanding of potential drug candidates by visualizing their effects on living organisms. This helps in identifying promising candidates and eliminating those with unfavorable characteristics earlier in the drug development process, saving time and resources. The shift toward personalized medicine requires a more thorough understanding of individual patients' conditions. Preclinical imaging can be used to assess disease heterogeneity and tailor treatment approaches, leading to more effective therapies.
Preclinical imaging techniques are generally non-invasive or minimally invasive, which is advantageous for both research animals and the accuracy of the data collected. This non-invasive nature enables longitudinal studies, reducing the need for sacrificing animals at multiple time points.
Hence, the increasing adoption of imaging systems for preclinical purposes may allow the growth of the market in the forecast period.
Restraint / Challenge
- Stringent Regulatory Framework for Product Approval
Regulatory bodies around the world have established strict guidelines and requirements for the approval of preclinical imaging products, which can create barriers for companies in the market and is a significant restraining factor on the growth of the global preclinical imaging market.
Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have implemented rigorous standards for product approval to ensure patient safety and the effectiveness of preclinical imaging products. These standards often include extensive preclinical testing, data submission, and adherence to Good Laboratory Practice (GLP) guidelines.
The regulatory process for preclinical imaging products is time-consuming and expensive. Companies conduct comprehensive studies to demonstrate the safety and efficacy of their products, which involves significant investment in research and development. In addition, the regulatory submission process requires extensive documentation, data analysis, and interaction with regulatory authorities, all of which add to the time and cost burden.
Furthermore, the stringent regulatory requirements may vary across different regions, creating additional challenges for companies operating in global markets. Companies must navigate the complex landscape of regulatory approvals in different countries, which can lead to delays in product launches and increased costs for compliance.
Thus, the stringent regulatory framework for product approval is a significant restraint on the growth of the global preclinical imaging market.
Global Preclinical Imaging Market Scope
The global preclinical imaging market is segmented into four notable segments based on product, reagents, application, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Systems
- Services
On the basis of product, the market is segmented into systems and services.
Reagents
- Preclinical Optical Imaging Reagents
- Preclinical Nuclear Imaging Reagents
- Preclinical MRI Contrast Agents
- Preclinical Ultrasound Contrast Agents
- Preclinical CT Contrast Agents
On the basis of reagents, the market is segmented into preclinical optical imaging reagents, preclinical nuclear imaging reagents, preclinical MRI contrast agents, preclinical ultrasound contrast agents, and preclinical CT contrast agents.
Application
- Research and Development
- Drug Discovery
- Bio-Distribution
- Cancer Cell Detection
- BioMarkers
- Others
On the basis of application, the market is segmented into research and development, drug discovery, bio-distribution, cancer cell detection, bio-markers, and others.
End User
- Contract Research Organization
- Pharmaceutical & Biotech Companies
- Academic & Government Research Institutes
- Diagnostics Center
- Others
On the basis of end user, the market is segmented into contract research organization, pharmaceutical & biotech companies, academic & government research institutes, diagnostics center, and others.
Global Preclinical Imaging Market Regional Analysis/Insights
The global preclinical imaging market is analyzed and market size insights and trends are provided by country, product, reagents, application, and end user.
The countries covered in this market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and rest of Middle East and Africa.
North America is expected to dominate the market with the largest market share due to growing demand for imaging devices. The U.S. is expected to dominate in the North America region due to rising technological advancements. Germany is expected to dominate in the Europe region due to the rising adoption of imaging systems. Japan is expected to dominate in the Asia-Pacific region due to the rising prevalence of neurological disorders.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Preclinical Imaging Market Share Analysis
The global preclinical imaging market competitive landscape provides details of the competitors. Details included are company overview, company financials, revenue generated, market potential, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major market players operating in the global preclinical imaging market are PerkinElmer Inc., FUJIFILM Visualsonics, Inc, Bruker, Hologic, Inc., Zeiss International, Agilent Technologies, Inc., Hamamatsu Photonics K.K., SOFIE, Cubresa Inc., Vieworks Co., Ltd., LI-COR, Inc., Aspect Imaging Ltd., Berthold Technologies GmbH & Co.KG, MILabs B.V, TriFoil Imaging, Mediso Ltd., IVIM Technology Inc., MR Solutions, Advanced Molecular Vision, Inc, AI4R, Photon etc, and KUB TECHNOLOGIES INC. among others.
SKU-